{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:34:28Z","timestamp":1772120068347,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s12185-017-2286-1","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T01:26:52Z","timestamp":1498699612000},"page":"655-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study"],"prefix":"10.1007","volume":"106","clinical-trial-number":[{"clinical-trial-number":"nct01456039","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-6920","authenticated-orcid":false,"given":"Dai","family":"Maruyama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohiko","family":"Hatake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masafumi","family":"Taniwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Ishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichi","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Kiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ikezoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Laille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tokihiro","family":"Ro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromi","family":"Tamakoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanae","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ohtsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"key":"2286_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1053\/j.seminhematol.2013.11.001","volume":"51","author":"L Karlin","year":"2014","unstructured":"Karlin L, Coiffier B. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies. Semin Hematol. 2014;51:25\u201334.","journal-title":"Semin Hematol"},{"key":"2286_CR2","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"J Vose","year":"2008","unstructured":"Vose J, Armitage J, Weisenburger D, International TCLP. International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124\u201330.","journal-title":"J Clin Oncol"},{"key":"2286_CR3","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1182\/blood-2010-09-310342","volume":"117","author":"DD Weisenburger","year":"2011","unstructured":"Weisenburger DD, Savage KJ, Harris NL, Gascoyne RD, Jaffe ES, MacLennan KA, et al. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117:3402\u20138.","journal-title":"Blood"},{"key":"2286_CR4","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","volume":"31","author":"V Mak","year":"2013","unstructured":"Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn LH, et al. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31:1970\u20136.","journal-title":"J Clin Oncol"},{"key":"2286_CR5","unstructured":"SEER Cancer Statistics Factsheets: Non-Hodgkin Lymphoma. National Cancer Institute. Bethesda, MD.\u00a0https:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed 17 Jan 2017."},{"key":"2286_CR6","first-page":"1764","volume":"54","author":"R Suzuki","year":"2013","unstructured":"Suzuki R. Guideline for T\/NK-cell lymphoma. Rinsho Ketsueki. 2013;54:1764\u20139.","journal-title":"Rinsho Ketsueki."},{"key":"2286_CR7","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","volume":"30","author":"B Pro","year":"2012","unstructured":"Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190\u20136.","journal-title":"J Clin Oncol"},{"key":"2286_CR8","first-page":"545","volume":"29","author":"MA Lunning","year":"2015","unstructured":"Lunning MA. Treatment of peripheral T-cell lymphoma: many shades of gray. Oncology (Williston Park). 2015;29:545\u201350.","journal-title":"Oncology (Williston Park)."},{"key":"2286_CR9","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","volume":"32","author":"M Ogura","year":"2014","unstructured":"Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, et al. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014;32:1157\u201363.","journal-title":"J Clin Oncol"},{"key":"2286_CR10","doi-asserted-by":"publisher","first-page":"e407","DOI":"10.3324\/haematol.2016.146977","volume":"101","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Karlin L, Radford J, Caballero D, Fields P, Chamuleau ME, et al. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma. Haematologica. 2016;101:e407\u201310.","journal-title":"Haematologica"},{"key":"2286_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.7164\/antibiotics.47.315","volume":"47","author":"H Ueda","year":"1994","unstructured":"Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J Antibiot (Tokyo). 1994;47:315\u201323.","journal-title":"J Antibiot (Tokyo)"},{"key":"2286_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.7164\/antibiotics.47.301","volume":"47","author":"H Ueda","year":"1994","unstructured":"Ueda H, Nakajima H, Hori Y, Fujita T, Nishimura M, Goto T, et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J Antibiot (Tokyo). 1994;47:301\u201310.","journal-title":"J Antibiot (Tokyo)"},{"key":"2286_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1006\/excr.1998.4027","volume":"241","author":"H Nakajima","year":"1998","unstructured":"Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res. 1998;241:126\u201333.","journal-title":"Exp Cell Res"},{"key":"2286_CR14","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.leukres.2008.12.013","volume":"33","author":"I Hartlapp","year":"2009","unstructured":"Hartlapp I, Pallasch C, Weibert G, Kemkers A, Hummel M, Re D. Depsipeptide induces cell death in Hodgkin lymphoma-derived cell lines. Leuk Res. 2009;33:929\u201336.","journal-title":"Leuk Res"},{"key":"2286_CR15","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1038\/bcj.2015.83","volume":"5","author":"BC Valdez","year":"2015","unstructured":"Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, et al. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J. 2015;5:e357.","journal-title":"Blood Cancer J."},{"key":"2286_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1158\/1078-0432.CCR-05-1225","volume":"12","author":"C Graham","year":"2006","unstructured":"Graham C, Tucker C, Creech J, Favours E, Billups CA, Liu T, et al. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res. 2006;12:223\u201334.","journal-title":"Clin Cancer Res"},{"key":"2286_CR17","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1182\/blood-2003-09-3068","volume":"103","author":"RL Piekarz","year":"2004","unstructured":"Piekarz RL, Robey RW, Zhan Z, Kayastha G, Sayah A, Abdeldaim AH, et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood. 2004;103:4636\u201343.","journal-title":"Blood"},{"key":"2286_CR18","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/S0006-2952(02)01261-3","volume":"64","author":"Y Sasakawa","year":"2002","unstructured":"Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, et al. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochem Pharmacol. 2002;64:1079\u201390.","journal-title":"Biochem Pharmacol"},{"key":"2286_CR19","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/j.1349-7006.2000.tb00899.x","volume":"91","author":"M Murata","year":"2000","unstructured":"Murata M, Towatari M, Kosugi H, Tanimoto M, Ueda R, Saito H, et al. Apoptotic cytotoxic effects of a histone deacetylase inhibitor, FK228, on malignant lymphoid cells. Jpn J Cancer Res. 2000;91:1154\u201360.","journal-title":"Jpn J Cancer Res"},{"key":"2286_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1349-7006.2001.tb01126.x","volume":"92","author":"H Kosugi","year":"2001","unstructured":"Kosugi H, Ito M, Yamamoto Y, Towatari M, Ito M, Ueda R, et al. In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD\/Shi-scid\/scid mice. Jpn J Cancer Res. 2001;92:529\u201336.","journal-title":"Jpn J Cancer Res"},{"key":"2286_CR21","first-page":"679","volume":"24","author":"N Sato","year":"2004","unstructured":"Sato N, Ohta T, Kitagawa H, Kayahara M, Ninomiya I, Fushida S, et al. FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells. Int J Oncol. 2004;24:679\u201385.","journal-title":"Int J Oncol"},{"key":"2286_CR22","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1167\/iovs.02-1052","volume":"44","author":"DD Klisovic","year":"2003","unstructured":"Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Investig Ophthalmol Vis Sci. 2003;44:2390\u20138.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"2286_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1359-4117.2002.01039.x","volume":"2","author":"JL Marshall","year":"2002","unstructured":"Marshall JL, Rizvi N, Kauh J, Dahut W, Figuera M, Kang MH, et al. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J Exp Ther Oncol. 2002;2:325\u201332.","journal-title":"J Exp Ther Oncol."},{"key":"2286_CR24","first-page":"718","volume":"8","author":"V Sandor","year":"2002","unstructured":"Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718\u201328.","journal-title":"Clin Cancer Res"},{"key":"2286_CR25","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-13-0095","volume":"19","author":"L Amiri-Kordestani","year":"2013","unstructured":"Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, et al. Phase I trial of a new schedule of romidepsin in patients with advanced cancers. Clin Cancer Res. 2013;19:4499\u2013507.","journal-title":"Clin Cancer Res"},{"key":"2286_CR26","doi-asserted-by":"publisher","first-page":"5827","DOI":"10.1182\/blood-2010-10-312603","volume":"117","author":"RL Piekarz","year":"2011","unstructured":"Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011;117:5827\u201334.","journal-title":"Blood"},{"key":"2286_CR27","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","volume":"30","author":"B Coiffier","year":"2012","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012;30:631\u20136.","journal-title":"J Clin Oncol"},{"key":"2286_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-7-11","volume":"7","author":"B Coiffier","year":"2014","unstructured":"Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Romidepsin for the treatment of relapsed\/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014;7:11.","journal-title":"J Hematol Oncol."},{"key":"2286_CR29","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"2286_CR30","unstructured":"JCOG-LSG. JCOG-LSG manual of clinical research for lymphoma and myeloma. 1st ed.\u00a0Tokyo, Japan: The Japan Foundation for Aging and Health; 2003. p. 68\u201373."},{"key":"2286_CR31","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"2286_CR32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3109\/10428194.2010.506569","volume":"51","author":"K Hashimoto","year":"2010","unstructured":"Hashimoto K, Kobayashi Y, Asakura Y, Mori M, Azuma T, Maruyama D, et al. Pneumocystis jiroveci pneumonia in relation to CD4+ lymphocyte count in patients with B-cell non-Hodgkin lymphoma treated with chemotherapy. Leuk Lymphoma. 2010;51:1816\u201321.","journal-title":"Leuk Lymphoma"},{"key":"2286_CR33","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NLE. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.","edition":"4"},{"key":"2286_CR34","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/annonc\/mdv596","volume":"27","author":"SJ Kim","year":"2016","unstructured":"Kim SJ, Kim JH, Ki CS, Ko YH, Kim JS, Kim WS. Epstein\u2013Barr virus reactivation in extranodal natural killer\/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin. Ann Oncol. 2016;27:508\u201313.","journal-title":"Ann Oncol"},{"key":"2286_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/j.1365-2141.2009.07954.x","volume":"148","author":"SE Bates","year":"2010","unstructured":"Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, et al. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol. 2010;148:256\u201367.","journal-title":"Br J Haematol"},{"key":"2286_CR36","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-08-1215","volume":"15","author":"S Woo","year":"2009","unstructured":"Woo S, Gardner ER, Chen X, Ockers SB, Baum CE, Sissung TM, et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009;15:1496\u2013503.","journal-title":"Clin Cancer Res"},{"key":"2286_CR37","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","volume":"29","author":"OA O\u2019Connor","year":"2011","unstructured":"O\u2019Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011;29:1182\u20139.","journal-title":"J Clin Oncol"},{"key":"2286_CR38","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","volume":"49","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49:2869\u201376.","journal-title":"Eur J Cancer"},{"key":"2286_CR39","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","volume":"3","author":"M Ogura","year":"2016","unstructured":"Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016;3:e107\u201318.","journal-title":"Lancet Haematol."},{"key":"2286_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15","author":"K Tsukasaki","year":"2016","unstructured":"Tsukasaki K, Tobinai K, Uchida T, Maeda Y, Shibayama H, Nagai H, et al. Phase 1\/2 study of forodesine in patients with relapsed peripheral T-cell lymphoma. J Clin Oncol. 2016. doi:10.1200\/JCO.2016.34.15","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-017-2286-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2286-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-017-2286-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:10:13Z","timestamp":1628597413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-017-2286-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2286"],"URL":"https:\/\/doi.org\/10.1007\/s12185-017-2286-1","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.730593243.793539742","asserted-by":"object"}]},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,29]]},"assertion":[{"value":"4 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"D.M. reports personal fees from Celgene during the conduct of the study; and outside the submitted work, honoraria and research funding from Takeda, Janssen, Eisai, Celgene, Kyowa Hakko Kirin, Ono, Mundipharma, and Chugai; research funding from GlaxoSmithKline, Servier, AbbVie, and MSD; and honoraria from Biomedis International, sanofi, Fujifilm, and Mochida Pharmaceutical Co. Ltd. K.To. reports grants and personal fees from Eisai, Takeda, Mundipharma, Kyowa Hakko Kirin, and Celgene; personal fees from HUYA Bioscience International during the conduct of the study; and outside the submitted work, personal fees from Zenyaku Kogyo; grants and personal fees from Janssen, Chugai Pharma, and Ono Pharmaceutical; and grants from GlaxoSmithKline, Servier, and AbbVie. M.O. reports research funding from SymBio and Celltrion; honoraria from AstraZeneca, Takeda, and Celgene; and advisory board personal fees from Mundipharma, MeijiSeika Pharma, and Celltrion outside of the submitted work. K.H. reports relationships\/conditions\/circumstances that may influence this work from AbbVie, Gilead, Celgene, Solasia, Pfizer, BMS, Janssen, Ono, and Chugai. K.Ts. reports grants from Celgene, Takeda, MundiPharma, and Chugai; and personal lecture fees from Zennyakukogyo, HUYA Biosciences, Chugai, and Kyowa Kirin outside of the submitted work. T.Is. reports personal fees from Celgene K.K. during the conduct of the study; and outside of the submitted work grants from Kyowa Hakko Kirin Co. Ltd, Bayer Pharma AG, and J-pharma Co. Ltd; and honoraria from Kyowa Hakko Kirin Co. Ltd. K.Is. reports grants and personal fees from Kyowa Kirin and Takeda during the conduct of the study; and personal fees from Cyugai, Janssen, Novartis, Ono, and Pfizer outside the submitted work. E.L., T.R., H.T., S.S., and T.O. are employed by and have received stock ownership from Celgene Corporation. T.U., K.A., M.T., N.K., Y.T., K.K., T.K., and T.Ik., have no relevant financial relationships to disclose. The study was designed under the responsibility of Celgene Corporation; the study was funded by Celgene K. K. (Tokyo, Japan); Romidepsin was provided by Celgene K.K. (Tokyo, Japan). Celgene K. K. (Tokyo, Japan) collected and analyzed the data and contributed to the interpretation of the study. All authors had full access to all of the data in the study and had final responsibility for the decision to submit for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}